These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10465727)

  • 1. L-carnitine use in hemodialyzed patients.
    Mantovani LG; Belisari A
    Am J Kidney Dis; 1999 Aug; 34(2):400-1. PubMed ID: 10465727
    [No Abstract]   [Full Text] [Related]  

  • 2. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin.
    Labonia WD
    Am J Kidney Dis; 1995 Nov; 26(5):757-64. PubMed ID: 7485128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anemia in chronic renal failure. The role of L-carnitine in the treatment of anemia of hemodialyzed patients].
    Wanic-Kossowska M; Kurzawska-Firlej D; Kaźmierski M; Czekalski S
    Pol Arch Med Wewn; 2003 Jan; 109(1):105-11. PubMed ID: 12879773
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients.
    Arduini A; Bonomini M; Clutterbuck EJ; Laffan MA; Pusey CD
    Nephrol Dial Transplant; 2006 Sep; 21(9):2671-2. PubMed ID: 16611680
    [No Abstract]   [Full Text] [Related]  

  • 5. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis.
    Verrina E; Caruso U; Calevo MG; Emma F; Sorino P; De Palo T; Lavoratti G; Turrini Dertenois L; Cassanello M; Cerone R; Perfumo F;
    Pediatr Nephrol; 2007 May; 22(5):727-33. PubMed ID: 17277954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-carnitine and erythropoietin requirements in hemodialysis patients.
    Kavadias D; Fourtounas C; Tsouchnikas J; Barboutis K
    Am J Kidney Dis; 1996 Jul; 28(1):156. PubMed ID: 8712214
    [No Abstract]   [Full Text] [Related]  

  • 8. Anemia and carnitine supplementation in hemodialyzed patients.
    Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
    Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reduction of hospitalization thanks to L-carnitine in hemodialyzed patients].
    Pérez-Oliva JF; Guillén Y; Gutiérrez F; Parodis Y
    Nefrologia; 2006; 26(4):499-500. PubMed ID: 17058866
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of low doses of recombinant human erythropoietin on the anemia in hemodialyzed patients.
    Okada K; Takahashi S
    Nephron; 1991; 59(4):689-90. PubMed ID: 1766524
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 12. L-carnitine treatment of anemia.
    Golper TA; Goral S; Becker BN; Langman CB
    Am J Kidney Dis; 2003 Apr; 41(4 Suppl 4):S27-34. PubMed ID: 12751051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference.
    Eknoyan G; Latos DL; Lindberg J;
    Am J Kidney Dis; 2003 Apr; 41(4):868-76. PubMed ID: 12666074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol.
    Vacha GM; Giorcelli G; Siliprandi N; Corsi M
    Am J Clin Nutr; 1983 Oct; 38(4):532-40. PubMed ID: 6624695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin.
    Matsumoto Y; Amano I; Hirose S; Tsuruta Y; Hara S; Murata M; Imai T
    Blood Purif; 2001; 19(1):24-32. PubMed ID: 11114574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of dialysis-related carnitine deficiency: three case studies.
    Lindberg J; Sadler R; Slowik M
    Nephrol News Issues; 2003 Apr; 17(5):73-6, 78. PubMed ID: 12715628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological use of L-carnitine in uremic anemia: has its full potential been exploited?
    Bonomini M; Zammit V; Pusey CD; De Vecchi A; Arduini A
    Pharmacol Res; 2011 Mar; 63(3):157-64. PubMed ID: 21138768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients.
    Sakurauchi Y; Matsumoto Y; Shinzato T; Takai I; Nakamura Y; Sato M; Nakai S; Miwa M; Morita H; Miwa T; Amano I; Maeda K
    Am J Kidney Dis; 1998 Aug; 32(2):258-64. PubMed ID: 9708610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialyzed children.
    Glöggler A; Bulla M; Fürst P
    Kidney Int Suppl; 1989 Nov; 27():S256-8. PubMed ID: 2636667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing anemia in the chronic hemodialysis patient.
    Norris SH; Kurtzman NA
    Int J Artif Organs; 1986 Jul; 9(4):199-206. PubMed ID: 3781644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.